Compare Amgen, Inc. (AMGN) vs Avalanche Treasury Corporation Class A Common Stock (AVAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Avalanche Treasury Corporation Class A Common Stock trades at $0.52 (market cap $21.30M). The key difference: Amgen, Inc. is far larger — about 9207.5× Avalanche Treasury Corporation Class A Common Stock's market cap, and Amgen, Inc. pays a 2.77% dividend while Avalanche Treasury Corporation Class A Common Stock pays none. Which is the better fit depends on your goals.
| AMGN | AVAT | |
|---|---|---|
Market Cap | $196.12B | $21.30M |
Sector | Health | Financials |
52-Week High | $388.16 | $10.75 |
52-Week Low | $271.18 | $0.51 |
Enterprise Value | $241.41B | $21.30M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
AVAT trades at $0.54, down 6.9% in the past 24 hours, with a bearish technical signal driven by moving averages. The company reported a net income of $8.28 million for 2025, but cash flow from operations was negative $930,710. Recent news highlights its Nasdaq listing, positioning it as an operating company focused on capital allocation within its ecosystem.
The outlook is mixed: low P/E of 12 and P/B of 0.4 suggest potential value, but negative operating cash flow and a bearish technical trend pose risks. Investor sentiment is cautious amid recent volatility, with institutional interest pending further financial stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →
